The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Maria Catherine Pietanza
Honoraria - Abbvie; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Novartis
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Novartis
Speakers' Bureau - PER; Quintiles
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); OncoMed (Inst); Stem CentRx (Inst)
 
Todd Michael Bauer
No Relationships to Disclose
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Neal Ready
Honoraria - Bristol-Myers Squibb; Celgene; Pfizer
 
Daniel Morgensztern
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genentech/Roche; Heat Biologics
Speakers' Bureau - Boehringer Ingelheim; Genentech/Roche
 
Bonnie S. Glisson
No Relationships to Disclose
 
Lauren Averett Byers
Consulting or Advisory Role - Abbvie; AstraZeneca; Biomarin; Medivation
Research Funding - Takeda
 
Melissa Lynne Johnson
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma (I); Otsuka (I)
Research Funding - Novartis
 
Howard A. Burris
No Relationships to Disclose
 
Francisco Robert
No Relationships to Disclose
 
Donald K Strickland
No Relationships to Disclose
 
Hany Zayed
Employment - Stem CentRx
 
Ramaswamy Govindan
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Abbvie; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Helsinn Therapeutics; Novartis
Research Funding - Abbvie (Inst); Bayer (Inst); GlaxoSmithKline (Inst); MethylGene (Inst)
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Celgene; Genentech; GlaxoSmithKline; Merck
 
Scott Dylla
Employment - Stem CentRx
Leadership - Stem CentRx
Stock and Other Ownership Interests - Stem CentRx
 
Stanford L. Peng
Employment - Stem CentRx